Shah Rajal B, Ghosh Debashis, Elder James T
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0932, USA.
Prostate. 2006 Sep 15;66(13):1437-44. doi: 10.1002/pros.20460.
The role of the epidermal growth factor receptor (ErbB1) in the progression of prostate cancer is incompletely understood.
Tissue microarrays from hormone-naive and advanced androgen-independent tumors were used to investigate the role of ErbB1 in prostate cancer progression.
ErbB1 expression in tumor tissues was strongly associated with hormone-refractory status (odds ratio = 6.67, 95% CI = (2.6, 17.4), P = 0.0001). However, ErbB1 overexpression was not a statistically significant covariate in a multivariate proportional hazards model for biochemical failure of hormone-naïve prostate cancer. Moreover, ErbB1 overexpression was not associated with tumor differentiation (P = 0.44), positive margins (P = 0.53), seminal vesicle invasion (P = 0.69), extraprostatic extension (P = 0.10), or preoperative PSA (P = 0.18) in the hormone-naïve group.
These findings are consistent with a model in which ErbB1 expression increases during the development of the androgen-independent state, and suggest that drugs targeted toward ErbB signaling could be of therapeutic relevance in the management of advanced prostatic carcinoma.
表皮生长因子受体（ErbB1）在前列腺癌进展中的作用尚未完全明确。
利用来自未经激素治疗及晚期雄激素非依赖肿瘤的组织芯片，研究ErbB1在前列腺癌进展中的作用。
肿瘤组织中ErbB1表达与激素难治状态密切相关（优势比=6.67，95%可信区间=(2.6, 17.4)，P = 0.0001）。然而，在未经激素治疗的前列腺癌生化复发的多变量比例风险模型中，ErbB1过表达并非具有统计学意义的协变量。此外，在未经激素治疗组中，ErbB1过表达与肿瘤分化（P = 0.44）、切缘阳性（P = 0.53）、精囊侵犯（P = 0.69）、前列腺外扩展（P = 0.10）或术前前列腺特异抗原（P = 0.18）均无关联。
这些发现与雄激素非依赖状态发展过程中ErbB1表达增加的模型一致，并提示针对ErbB信号的药物在晚期前列腺癌治疗中可能具有治疗意义。
